You have to take the risks and that's the nature of stock market.
Put it this way, if you are paying $15 right now, the chance it's going to $30 in about 1 year or two years is about 20% - 30%, but the chance it's going back where it was at $7 - $8 in a few months is about 20% - 30%, the chance it's going go zero in a few years is also very low at 10% - 20% since the drug is still on trial, the chance it's going to zero in more than three to five years is actually higher if the drug failed at 50% - 60%(a lot of drugs failed, fair enough right?).
Anyway, above is just my estimation.
To sum it up, it's a high risk stock especially after the recent run up and down and the stock price has more than doubled than before the run.
As to the stock price, my estimation is that the chance it would fill the gap between $10 - $11 is high at 30% - 40%.
At $10, you have the chance to triple at about 20% - 30% in two years.
But at $10, you also have the chance at about 50% - 60% to lose everything in about three to five years and that's why not many institutions are into it.
So it's a high risk stock which I would not touch.
Hope the shorts would be able to cover...
I trust the management that it's a great move to acquire LS9.
We will get more details on the report on March 7
Phase IIb and phase III would take years to finish.
Phase IIa was only for 30 patients in just one week, you could't tell any side effect in such a short time and that's why the rest of the trials would take years to finish.
The risk is high if it failed years long trials.
From the stock price action, the result might be just more trials are required.
Greedy is the enemy of investors.
No matter what the result is, I am sure it has been reflected into the stock price.
The institutions have been come short now.
Small investors will be killed if they don't run fast enough.
Sentiment: Strong Sell
If the result on Jan 30 is positive, this should have been trading above $30 now just a few days before the result. To me, it's gambling.